Could immune therapy ease sudden OCD and eating refusal in kids?
NCT ID NCT04609761
First seen Mar 08, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This study tested monthly infusions of intravenous immunoglobulin (IVIG) for 6 months in 17 children aged 4–17 with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), a condition marked by sudden, severe OCD or food refusal. The goal was to see if IVIG could reduce symptoms and improve daily functioning. Because it was a small, open-label trial without a placebo group, the results are preliminary and need confirmation in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANS PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gillberg Neuropsychiatry Centre
Gothenburg, 411 19, Sweden
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Intravenous immunoglobulin (IVIG, brand name Privigen)
What this could lead to
If it works, this could point toward a treatment that reduces severe neuropsychiatric symptoms in children with PANS.
What could go wrong
This is a small, early-phase trial with only 17 participants and no placebo group, so results may not be reliable or apply to all children. IVIG can cause side effects like headaches, fever, or allergic reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.